FDA Approves Ahzantive, a Biosimilar to Eylea
Formycon AG and Klinge Biopharma GmbH jointly announced that the U.S. Food and Drug
Administration (FDA) approved FYB203/Ahzantive®. Ahzantive is an injectable vascular endothelial growth factor (VEGF) inhibitor that is a biosimilar to Eylea (aflibercept), and is approved to treat the following eye conditions:
- Neovascular (Wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR).
